The inflammatory markers modification in patients with chronic obstructive pulmonary disease The comparative efficiency of long term use of fenspirid and atrovent in 42 patients with chronic obstructive pulmonary disease was studied. It was noted that the 6 months administration of fenspirid contributed to a 2,6 times cough intensity decrease and atrovent – a 1,2 time decrease. The anti-inflammatory therapy had a positive effect on the level of proinflammatory cytokines that registered a 3 times decrease in patients that used fenspirid and 1,5 time decrease after atrovent. During the long term treatment with fenspirid VEF1 increased by 35,5% and by 21,2% - during the basic therapy.

La 42 bolnavi cu bronhopneumapatie cronică obstructivă a fost studiată eficacitatea comparativă a tratamentului de durată cu fenspirid şi Atrovent. A fost stabilit că administrarea fenspiridului timp de 6 luni duce la micşorarea tusei de 2,6 ori, iar Atrovent – de 1,2 ori. Terapia antiinflamatorie a avut efect asupra citokinelor proinflamatoare, care s-au micşorat pe fon de tratament cu fenspirid de 3 ori, iar cu Atrovent de 1,5 ori. În rezultatul tratamentului de durată cu fenspirid VEMS a crescut cu 35,5%, iar pe fon de tratament de bază numai cu 21,2%.